Article Text

PDF
Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study
  1. M D M Haag1,
  2. A Hofman1,
  3. P J Koudstaal2,
  4. B H C Stricker1,3,4,
  5. M M B Breteler1
  1. 1
    Department of Epidemiology, Erasmus Medical Centre, Rotterdam, The Netherlands
  2. 2
    Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands
  3. 3
    Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
  4. 4
    Inspectorate for Health Care, The Hague, The Netherlands
  1. Professor M M B Breteler, Department of Epidemiology, Erasmus Medical Centre, PO Box 2040, 3000 CA Rotterdam, The Netherlands; m.breteler{at}erasmusmc.nl

Abstract

Background: Cross-sectional reports suggest that statin users are less likely to have Alzheimer disease (AD). Prospective studies have provided inconsistent evidence. Moreover, it is unclear whether the association differs for lipohilic statins, those that could more easily pass the blood–brain barrier and hydrophilic statins.

Objectives: To prospectively evaluate whether use of statins is associated with the risk of AD, and to determine whether associations differ for lipophilic and hydrophilic statins.

Method: 6992 participants of the prospective, population-based Rotterdam Study were followed, from baseline (1990–1993) until January 2005 for incident AD. Data on all filled prescriptions came from pharmacy records. For each date on which each event occurred, cholesterol-lowering drug use for the person who experienced the event and all remaining persons in the cohort was categorised as “any” or “never” use. A distinction was made between statin, lipophilic and hydrophilic statins, and non-statin cholesterol-lowering drugs. Data were analysed with the Cox regression analysis, adjusting for sex, age and potential confounders.

Results: During follow-up (mean 9 years), 582 persons developed AD. Compared with never use of cholesterol-lowering drugs, statin use was associated with a decreased risk of AD (HR 0.57; 95% CI 0.37 to 0.90), but non-statin cholesterol-lowering drug use was not (HR 1.05; 95% CI 0.45 to 2.44). HRs were equal for lipophilic (HR 0.54; 95% CI 0.32 to 0.89) and hydrophilic statins (HR 0.54; 95% CI 0.26 to 1.11).

Conclusion: In the general population, the use of statins, but not of non-statin cholesterol-lowering drugs, was associated with a lower risk of AD compared with never use of cholesterol-lowering drugs. The protective effect was independent of the lipophilicity of statins.

Statistics from Altmetric.com

Footnotes

  • See Editorial Commentary, p 1

  • Funding: The Rotterdam Study is supported by the Erasmus Medical Centre and Erasmus University Rotterdam, The Netherlands Organization for Scientific Research, The Netherlands Organization for Health Research and Development, the Research Institute for Diseases in the Elderly, the Ministry of Education, Culture and Science, the Ministry of Health, Welfare and Sports, the European Commission and the Municipality of Rotterdam. No additional support was obtained for this particular study. The study sponsors had no involvement in the study design; collection, analysis and interpretation of data; writing of the report; or the decision to submit the paper for publication.

  • Contributors: MDMH contributed to the study design, performed the data analysis and drafted the manuscript. PJK contributed to the data collection. AH contributed to the study design. BHCS and MMBB contributed to the study design, data analysis and drafting of the manuscript. All authors had full access to all data in the study. All authors reviewed, edited and approved the final version of the manuscript.

  • Competing interests: None.

  • Ethics approval: Ethics approval was provided by the medical ethics committee of the Erasmus Medical Centre, Rotterdam, The Netherlands.

  • Patient consent: Obtained.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Editorial commentary
    Larry Sparks